For example, in KIRC patients with low expression of Purinergic genes, the use of HDAC inhibitors targeting HDAC8, HDAC10, and HDAC11 may help to inhibit the invasive and metastatic ability of tumor cells, which is closely associated with a good prognosis for patients. The gene discussed is HDAC10; the disease is neoplasm.